A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Clinical trial NCT04535986 · COMPLETED

Trial details

NCT number: NCT04535986
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Obstructive Pulmonary Disease

Start date: 2020-09-29
Primary completion: 2022-09-12
Enrollment: 763

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.